Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
Hisse Senetlerindeki Sıralama #25864
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Hisse Fiyatı
$1.21
Piyasa Değeri
$45.55M
Değişim (1 gün)
-2.43%
Değişim (1 yıl)
-34.60%
Ülke
US
Ticaret Metagenomi, Inc. Common Stock (MGX)

Kategori

Metagenomi, Inc. Common Stock (MGX) için kazanç
2026 itibarıyla kazanç TTM: 0
Metagenomi, Inc. Common Stock şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Metagenomi, Inc. Common Stock için kazanç geçmişi 2026 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$-3.09B -
US